Slide 1: Disclaimer
2 DISCLAIMER All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements, including the company’s revised revenue guidance
Slide 2: Glaukos is transforming glaucoma therapy
3 is transforming glaucoma therapy LARGE MARKET Growing $5.1bn global opportunity1 UNMET NEED Significant drawbacks of current treatments DEMONSTRATED EXECUTION Broad reimbursement and highly successful launch JUST THE BEGINNING Advanced portfolio of micro-scale injectable therapies 1 Market Scope e
Slide 3: Aging Population Drives Glaucoma Prevalence
US GLAUCOMA POPULATION1 Reducing IOP is the only proven treatment for glaucoma Aging Population Drives Glaucoma Prevalence 1 Market Scope estimates for glaucoma prevalence; excludes ocular hypertension 2 Market Scope estimates for total global glaucoma market Typically associated with elevated intra
Slide 4: How The Eye's Drainage System Works
5 How The Eye’s Drainage System Works Elevated IOP occurs when aqueous humor outflow through the trabecular meshwork and into Schlemm’s canal is reduced due to degeneration and obstruction Secondary outflow pathway is the suprachoroidal space
Slide 5: Conventional Glaucoma Treatment Options
6 Conventional Glaucoma Treatment Options Laser Prescription Eye Drops 01 High non-compliance rates Complex, frequent and lifelong dosing regimens; adverse side effects Recurring expense for patient and payor 02 Effects dissipate within 1-5 years Repeat procedures less effective Medication may still
Slide 6: iStent vs. Conventional Surgery
7 Conventional Surgery iStent vs. Conventional Surgery
Slide 7: Our Solution Portfolio: Transformational Shift to Micro-Scale Injectable Therapy
8 Our Solution Portfolio: Transformational Shift to Micro-Scale Injectable Therapy RESTORE FLOW FURTHER ENHANCE FLOW COMBINATION DRUG & FLOW iStent Inject, iStent Supra and iDose are not approved by the FDA. iStent Inject and iStent Supra are currently being evaluated in IDE clinical trials; a Phase
Slide 8: Comprehensive Clinical Results
9 Comprehensive Clinical Results
Slide 9: Comprehensive Clinical Results: What We Are Discovering
Recent published peer-reviewed clinical results show improvement over 2008 IDE pivotal trial iStent + cataract surgery patients achieved IOP < 15 mm Hg at 3 years1 65% of phakic/pseudophakic patients achieved postoperative IOP < 15 mm Hg without medications at 12 months with single iStent2 iStent +
Slide 10: US Pivotal Trial Results
11 p = 0.004 p = 0.010 Primary Endpoint IOP < 21 mm Hg w/o meds Secondary Endpoint IOP > 20% w/o meds iStent + Cataract Surgery (n=117) AT 12 MONTHS US Pivotal Trial Results FDA Approved June 2012: iStent Shown to Reduce IOP Cataract Surgery Only (n=123) First prospective, randomized, open label, mu
Slide 11: Single iStent + Cataract Surgery Achieves < 15 mm Hg Through 3 Years
12 Compelling Clinical Results: Single iStent + Cataract Surgery Achieves < 15 mm Hg Through 3 Years Consecutive series of 62 eyes; decision to implant based on patient desire to reduce topical meds and intent to offer surgical treatment with favorable safety profile In consistent cohort of 39 eyes
Slide 12: Long-term Efficacy of iStent + Cataract Surgery Shown in International Study
13 Compelling Clinical Results: Long-term Efficacy of iStent + Cataract Surgery Shown in International Study + CATARACT SURGERY Prospective, non-comparative, uncontrolled, non-randomized, interventional case series study of 19 patients with uncontrolled mild-to-moderate OAG using 1 or more topical g
Slide 13: International Study Shows IOP-Lowering Capability of 1, 2 and 3 iStents
14 Compelling Clinical Results: International Study Shows IOP-Lowering Capability of 1, 2 and 3 iStents Prospective, randomized study of 119 OAG patients with preoperative unmedicated IOP of 22-38 mm Hg Safety data similar across all stent groups Demonstrates potential to titrate treatment based on
Slide 14: International Study Shows IOP-Lowering Capability of 1, 2 and 3 iStents
15 Compelling Clinical Results: International Study Shows IOP-Lowering Capability of 1, 2 and 3 iStents Prospective, randomized study of 119 OAG patients with preoperative unmedicated IOP of 22-38 mm Hg Safety data similar across all stent groups IOP < 15 mm Hg IOP < 18 mm Hg IOP > 20% vs baseline %
Slide 15: International Study of Dual Physiologic Outflow in Failed Trab Patients
16 Compelling Combination Clinical Results: International Study of Dual Physiologic Outflow in Failed Trab Patients + + 1 Medication Mean IOP (mm Hg) Myers S. AGS 2016 The iStent is approved in the European Union and certain other international markets for use either in combination with cataract sur
Slide 16: Clinical Research Program Statistics
18 17 Prospective clinical trials currently underway Clinical Research Program Statistics 45 Articles published in peer-reviewed journals
Slide 17: Global Commercial Operations
18 Global Commercial Operations
Slide 18: Seizing First Mover Opportunity in Targeted Markets
19 Seizing First Mover Opportunity in Targeted Markets: Commercial Execution Highlights Since US FDA Approval US Market Development US Reimbursement International Expansion Highly successful launch of new market medical device in ophthalmology Delivered strong revenue and surgeon adoption growth rat
Slide 19: Q2 2016 Financial & Operational Performance
45 52 20 in Q2 2015 in Q2 2016 TOTAL NET SALES (in millions) 16% year-over-year growth in domestic sales organization 61% year-over-year growth in net sales Q2 2016 Financial & Operational Performance: Growth Reflects iStent Adoption Trends Avg. Number of US Sales Reps 17.8 28.6 $0 $5 $10 $15 $20 $2
Slide 20: Current & Future Potential MIGS Market Participants
21 Current & Future Potential MIGS Market Participants ALCON cypass 6.35mm suprachoroidal device for implantation into supraciliary space using guidewire delivery (actual) Ivantis hydrus 8mm nitinol scaffolding device implanted into Schlemm’s canal (image) iStent iStent Inject CyPass Hydrus
Slide 21: Strong net sales growth driven by increased iStent utilization
22 Strong net sales growth driven by increased iStent utilization across an expanding customer base Financial Summary $20.9 $45.6 $71.7 NET SALES (IN MILLIONS) 1H: $51.6 Six months ended June 30 GROSS MARGIN 81% 86%* Favorable gross margin reflects efficient manufacturing and cost structure Continue
Slide 22: Growth Strategies: Establishing MIGS as OAG Standard of Care
23 Increase US iStent adoption with seasoned sales force, broad reimbursement coverage and compelling clinical results Growth Strategies: Establishing MIGS as OAG Standard of Care 01 Secure FDA approvals with expanded indications for iStent pipeline products 02 Develop, secure regulatory approval fo
Slide 23: Growth Strategies: Establishing MIGS as OAG Standard of Care
Growth Strategies: Establishing MIGS as OAG Standard of Care 01 02 03 04 Increase US iStent ‘Secure FDA approvals Develop, secure ‘adoption with seasoned with expanded regulatory approval for sales force, broad indications for iStent. ‘and commercialize Dose reimbursement coverage pipeline products
Slide 24: Glaukos
GLAUK@S